Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.69 |
| ▸ | DHFR | P00374 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL332569 | 0.82 | TSHR (0.70) | AURKADHFRLMNATSHRKMT2A | |
| SCHEMBL12306892 | 0.81 | ALDH1A1 (0.87) | AURKADHFRLMNATSHRKMT2A | |
| Sulfadiazine SCHEMBL24176 | 0.81 | LMNA (1.00) | AURKADHFRLMNATSHRKMT2A | |
| SCHEMBL9209077 | 0.81 | AURKA (0.69) | AURKADHFRLMNATSHRKMT2A | |
| Sulfadiazine SCHEMBL10422849 | 0.81 | LMNA (1.00) | AURKADHFRLMNATSHRKMT2A | |
| Sulfadiazine SCHEMBL30080807 | 0.81 | LMNA (1.00) | AURKADHFRLMNATSHRKMT2A | |
| SCHEMBL6284075 | 0.81 | EDNRB (0.56) | AURKADHFRLMNATSHRALDH1A1 | |
| SCHEMBL13962914 | 0.81 | ALDH1A1 (0.74) | LMNAKMT2AMEN1KDM4EALDH1A1 | |
| Sulfadiazine SCHEMBL34517 | 0.80 | LMNA (0.96) | AURKADHFRLMNATSHRKMT2A | |
| Sulfadiazine SCHEMBL16860643 | 0.80 | LMNA (0.96) | AURKADHFRLMNATSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215594-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-29 | — | — | US | disclosed |
| US-6919371-B2 | 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040072828-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2004-04-15 | — | — | US | disclosed |
| US-6660752-B2 | Adrenergic blocking agents | BAYER PHARMACEUTICALS CORPORATION | 2003-12-09 | — | — | US | disclosed |
| US-20030078260-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215594-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | AURKA 2232/4885DHFR 4801/4885LMNA 1359/4885 |
| US-20040072828-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | AURKA 2232/4885DHFR 4801/4885LMNA 1359/4885 |
| US-20030078260-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | AURKA 2232/4885DHFR 4801/4885LMNA 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.